Shanda Group has entered a period of renewed visibility, with a series of incubated ventures coming to light over the past several months. At the center of this momentum is its founder, Tianqiao Chen, ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Schroeder, who is 28 and lives in Fargo, North Dakota, texts Cole “all day, every day” on OpenAI’s app. In the morning, he ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...

In its second major partnership with a big pharma group, UK-based AI and multi-omics company Relation Therapeutics has agreed to seek out targets for allergic diseases on behalf of Novartis. The ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...